# Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)

> **NCT01479764** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 154 (actual)

## Conditions studied

- Surgical Procedures, Elective

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Neostigmine
- **DRUG:** Glycopyrrolate

## Key facts

- **NCT ID:** NCT01479764
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-02
- **Primary completion:** 2012-10-26
- **Final completion:** 2012-11-05
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2017-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01479764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01479764, "Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01479764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*